6-氯咪唑并[1,2-B]哒嗪-2-甲酸乙酯 | 64067-99-8

• 物质功能分类: 医药中间体 - 杂环化合物 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 6-氯咪唑并[1,2-B]哒嗪-2-甲酸乙酯
• 中文别名: 6-氯咪唑[1,2-B]并哒嗪-2-甲酸乙酯；乙基6-氯-1,5-二氢咪唑并[1,2-b]哒嗪-2-羧酸酯；6-氯咪唑并[1,2-b]哒嗪-2-甲酸乙酯
• 英文名称: ethyl 6-chloroimidazo[1,2-b]pyridazine-2-carboxylate
• CAS: 64067-99-8
• 化学式: C₉H₈ClN₃O₂
• mdl: MFCD03086230
• 分子量: 225.634
• InChiKey: AZEPEWATPYRPBM-UHFFFAOYSA-N

物化性质

• 熔点：
  155-158
• 密度：
  1.47±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿、二氯甲烷、乙酸乙酯、甲醇

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  2-8°C

SDS

Name:	Ethyl 6-chloroimidazo[1 2-b]pyridazine-2-carboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	64067-99-8

Section 1 - Chemical Product MSDS Name:Ethyl 6-chloroimidazo[1 2-b]pyridazine-2-carboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
64067-99-8	Ethyl 6-chloroimidazo[1,2-b]pyridazine	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 64067-99-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: beige
Odor: odorless - slight odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 155 - 158 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H8ClN3O2
Molecular Weight: 225.63

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 64067-99-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 6-chloroimidazo[1,2-b]pyridazine-2-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 64067-99-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 64067-99-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 64067-99-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  6-氯咪唑并[1,2-B]哒嗪-2-甲酸乙酯 在 lithium hydroxide monohydrate 作用下， 以 甲醇 、 水 为溶剂， 反应 0.25h， 以76%的产率得到6-methoxyimidazo[1,2-b]pyridazine-2-carboxylic acid
  参考文献：
  名称：

  [EN] SPIROHEPTANE SALICYLAMIDES AND RELATED COMPOUNDS AS INHIBITORS OF ROCK
  [FR] SALICYLAMIDES DE SPIROHEPTANE ET COMPOSÉS ASSOCIÉS UTILISÉS COMME INHIBITEURS DE ROCK

  摘要：

  本发明提供了式(I)的化合物：或立体异构体、互变异构体或药用可接受的盐，其中所有变量如本文所述定义。这些化合物是选择性的ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用同一化合物治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。

  公开号：

  WO2017123860A1
• 作为产物：
  描述：

  3-氨基-6-氯哒嗪 、 3-溴丙酮酸乙酯 以 乙醇 为溶剂， 反应 18.0h， 以46%的产率得到6-氯咪唑并[1,2-B]哒嗪-2-甲酸乙酯
  参考文献：
  名称：

  蛋白酶激活受体2的强效拮抗剂，可抑制人类癌细胞中的多种信号传导功能。

  摘要：

  蛋白酶激活受体2（PAR2）是一种细胞表面蛋白，与G蛋白依赖性和独立的细胞内信号传导途径相关，可产生各种生理反应，包括与代谢，炎症，疼痛和癌症有关的生理反应。已知某些蛋白酶，肽和非肽能有效激活PAR2。然而，尽管它们具有预期的治疗潜力，但尚未报道有效的有效PAR2拮抗剂。这项研究调查了咪唑并哒嗪化合物I-191（4-（8-（叔丁基）-6-（4-氟苯基）咪唑并[1,2-b]哒嗪-2 -羰基）-3,3-二甲基哌嗪-2-酮）。在纳摩尔浓度下，I-191抑制PAR2的结合并通过结构上不同的PAR2激动剂（胰蛋白酶，肽，在人类结肠腺癌II级细胞系（HT29）的细胞中以浓度依赖的方式表达）。I-191强烈减弱了多个PAR2介导的细胞内信号传导途径，导致Ca2 +释放，细胞外信号调节激酶1/2（ERK1 / 2）磷酸化，Ras同源基因家族，成员A（RhoA）激活以及对福司可林诱导的抑制cAMP积累。在H

  DOI：

  10.1124/jpet.117.245027

文献信息

• Visible Light-Promoted Aliphatic C–H Arylation Using Selectfluor as a Hydrogen Atom Transfer Reagent
  作者：Hong Zhao、Jian Jin

  DOI：10.1021/acs.orglett.9b01635

  日期：2019.8.16

  A mild, practical method for direct arylation of unactivated C(sp3)–H bonds with heteroarenes has been achieved via photochemistry. Selectfluor is used as a hydrogen atom transfer reagent under visible light irradiation. A diverse range of chemical feedstocks, such as alkanes, ketones, esters, and ethers, and complex molecules readily undergo intermolecular C(sp3)–C(sp2) bond formation. Moreover, a

  通过光化学已经实现了一种温和的，实用的方法，用于将未激活的C（sp 3）–H键与杂芳烃直接芳基化。Selectfluor在可见光照射下用作氢原子转移试剂。各种各样的化学原料，例如烷烃，酮，酯和醚，以及复杂的分子容易形成分子间的C（sp 3）–C（sp 2）键。此外，可通过此处介绍的方案有效地烷基化各种杂芳烃，包括药学上有用的支架。
• [EN] HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE PRMT5
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2019102494A1

  公开（公告）日：2019-05-31

  The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.

  公式I、公式Ia和公式Ib的化合物以及它们的类似物、互变异构体、对映异构体、多态性、水合物、溶剂化物、药物可接受的盐、药物组合物、代谢物和前药在本文件中进行了描述。这些化合物抑制PRMT5，并可作为治疗或改善与细胞生长相关的疾病，如恶性肿瘤、精神分裂症、阿尔茨海默病、帕金森病等的治疗或改善剂。
• NASAL DROPS CONTAINING FUSED PYRIDAZINE DERIVATIVES
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1243271A1

  公开（公告）日：2002-09-25

  A nose drop containing the compound (I) represented by the formula wherein Ar1 and Ar2 are each an aromatic group, Ar1 and Ar2 optionally form a condensed cyclic group together with the adjacent carbon atom, ring B is a nitrogen-containing heterocycle, X and Y are each a bond, an oxygen atom or S(O)p (p is 0 to 2), NR4 (R4 is H or a lower alkyl group) or a divalent linear lower hydrocarbon group optionally having substituents and containing 1 to 3 heteroatoms, A is N or CR7 (R7 is H, a halogen atom, a hydrocarbon group, an acyl group or a hydroxy group optionally having substituents), R1, R2 and R3 are each H, a halogen atom, a hydrocarbon group, an acyl group or a hydroxy group optionally having substituents, and R8 is H, a hydroxy group optionally substituted by a lower alkyl group or a carboxyl group, provided that the nitrogen-containing heterocycle represented by ring B is not a heterocycle represented by the formula wherein n is 0 - 1, or a salt thereof or a prodrug thereof, exhibits a superior prophylactic or therapeutic effect on allergic rhinitis and the like.

  一种含有由以下公式表示的化合物（I）的鼻滴 其中Ar1和Ar2各自是芳香基团，Ar1和Ar2可以与相邻的碳原子一起形成紧凑的环状基团，环B是含氮杂环，X和Y各自是键，氧原子或S（O）p（p为0至2），NR4（R4为H或低碳基团）或二价线性低碳氢基团，可选地具有取代基并含有1至3个杂原子，A为N或CR7（R7为H、卤素原子、碳氢基团、酰基或可选地具有取代基的羟基），R1、R2和R3各自为H、卤素原子、碳氢基团、酰基或可选地具有取代基的羟基，以及 R8为H、可选地由低碳基团或羧基取代的羟基，前提是由环B表示的含氮杂环不是由以下公式表示的杂环 其中n为0-1，或其盐或前药，对过敏性鼻炎等表现出卓越的预防或治疗作用。
• Visible-light-mediated minisci C–H alkylation of heteroarenes with 4-alkyl-1,4-dihydropyridines using O₂ as an oxidant
  作者：Jianyang Dong、Fuyang Yue、Wentao Xu、Hongjian Song、Yuxiu Liu、Qingmin Wang

  DOI：10.1039/d0gc02111c

  日期：——

  Minisci C–H alkylation of N-heteroarenes with 4-alkyl-1,4-dihydropyridines at room temperature with molecular oxygen as an oxidant was developed.

  在室温下，使用分子氧作为氧化剂，开发了米尼斯基C-H与N-杂环芳烃的4-烷基-1,4-二氢吡啶的烷基化反应。

• [EN] INHIBITORS OF PROTEASE ACTIVATED RECEPTOR-2<br/>[FR] INHIBITEURS DU RÉCEPTEUR-2 ACTIVÉ DE PROTÉASE
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2019124567A1

  公开（公告）日：2019-06-27

  The present invention relates generally to compounds capable of inhibiting Protease Activated Receptor-2 (PAR2), and uses thereof. More specifically, the present invention relates to inhibitors of PAR2, to their preparation, and to their use in the treatment of diseases and disorders mediated by PAR2 signaling.

  本发明一般涉及能够抑制蛋白酶活化受体-2（PAR2）的化合物，以及它们的用途。更具体地说，本发明涉及PAR2的抑制剂，它们的制备以及它们在治疗由PAR2信号传导介导的疾病和紊乱中的应用。